ArticleJHEP reports : innovation in hepatology2026
Loss of hepatocyte PI3Kα reduces hepatocellular carcinoma and hepatocyte proliferation in association with altered lipid metabolism.
Article in JHEP reports : innovation in hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND &
aimsHepatocellular carcinoma (HCC) is a disease with an increasing incidence and a high mortality rate. Thus, targeted therapies for HCC are urgently needed. Phosphoinositide 3-kinase (PI3K)-AKT-mTORC1 signaling is frequently induced in solid tumors and is associated with tumor progression and with the most aggressive type of HCC. However, complete inhibition of all PI3K isoforms is unlikely to achieve a favorable therapeutic index for HCC treatment because of on-target side effects. In this study, we determined the role of hepatocyte PI3Kα activity in HCC.
methodsWe investigated the role of hepatocyte PI3Kα in HCC using conditional knockout mice in the N-nitrosodiethylamine (DEN) plus high-fat diet (HFD) model of HCC.
resultsMice lacking PI3Kα in hepatocytes were protected from DEN-induced HCC (n = 8-17, p <0.005). PI3Kα in hepatocytes was dispensable for AKT phosphorylation in HCC and normal liver (n = 4). It was also dispensable for AKT phosphorylation in hepatocytes during compensatory proliferation following acute administration of the hepatocarcinogen (n = 3-4). AKT phosphorylation induced by hepatocyte growth factor (HGF) and epidermal growth factor (EGF) was mediated by redundant PI3Kα and PI3Kβ activities (n = 3-4). Nonetheless, mice lacking hepatocyte PI3Kα showed reduced HCC proliferation and reduced hepatocyte proliferation acutely induced by DEN and by HGF and EGF (n = 3, p <0.05). This phenotype was associated with a gene expression signature indicating altered lipid metabolism and reduced formation of lipid droplets (n = 7).
conclusionsTogether, these results indicate PI3Kα as a promising target for the treatment of HCC. IMPACT AND IMPLICATIONS: Class-1 PI3Ks are frequently activated in tumors, but complete inhibition of PI3K signaling is associated with liver damage and HCC. We showed that selective ablation of the PI3Kα isoform in hepatocytes drastically reduced HCC development in mice injected with a hepatocarcinogen. This phenotype was associated with reduced hepatocyte proliferation and a gene expression signature indicative of altered lipid metabolism and reduced lipid droplet formation. Overall, our results indicate PI3Kα as a promising drug target for the treatment of HCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.